anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention refers to the composition of substances to prevent and treat endothelial cell-mediated disorders with pathological differentiation of endothelial cells, for example, in response to insulin, lipids, lipoproteins or LA-paf. The invention refers to simple methods to test and use antagonists against LA-paf, paf and very high affinity receptors on endothelial cells which can also be cultured on soluble particles for screening procedures. According to the invention genes producing very high affinity receptors, for example, in response to growth factors such as insulin. These genes can be transferred from adherent endothelial cell lines to soluble cells using standard procedures. Antagonists against LA-paf, paf and very high affinity receptors are administered by preference to healthy persons having risk factors to protect against aging and metabolic, genetic, chronicle, idiopathic, inflammatory or degenerative disorders. The antagonists can be administered by preference with food or topically, for example, with beauty products.
Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
Postpartum Intervention for Mothers with Opioid Use Disorders - Brain-Behavior Mechanisms Opioid use disorder (OUD) is a fast-growing and devastating epidemic in the US with many suffering comorbid mood disorders. Despite receiving "gold standard" buprenorphine treatment to reduce withdrawal, OUD mothers still suffer have cravings, depression, impaired interpersonal interactions and maladaptive parenting behaviors that may lead to child maltreatment and costly utilization of foster care. Parenting interventions have been established to improve parent mood and sensitive caregiving behaviors for high-risk non-OUD populations. "Mom Power" (MP) is an evidence-based 13-session psychosocial mother-child intervention established to enhance emotionally sensitive caregiving, while concurrently reducing parental stress and depression for non-OUD mothers. The investigators have demonstrated feasibility of with virtual MP (vMP) and for MP with substance use disorders. However, vMP for mothers with OUD has not been studied with respect to drug use reduction or mood improvement. The investigators have also established brain mechanisms that regulate parenting. Recent work from the investigators has established that a parenting intervention for non-OUD mothers was associated with a larger enhancement of evoke potential responses (ERPs) for emotional faces relative to neutral faces and that the magnitude of ERP responses to emotional faces was associated with observed maternal sensitivity. Using functional magnetic resonance imaging (fMRI) of the brain, the investigators have also established a Maternal Behavior Neurocircuit (MBN) that regulates flexible responses to the demands of their own infant - such as to the unique, ethologically salient own-baby cry and face stimuli during the early postpartum period. The investigators have established fMRI maternal brain changes associated with MP in non-OUD mothers, and brain effects of OUD on mothers. However, it is unknown how parental brain mechanisms through which parenting interventions may work for mothers with OUD, such as affecting ERP or fMRI responses to baby stimuli in the MBN. Central hypotheses: Mothers with OUD who get virtual MP (vMP), compared to matched controls, will show improved drug craving, mood, and stress symptoms, via changes in pre-specified MBN brain regions. In the high-risk R61 phase, the investigators will establish if vMP (n=25) for OUD can be implemented and improve mood, reduce drug use and affect ERP brain responses to baby pictures compared with control (n=25). If hypotheses in the R61 are confirmed, the investigators will confirm and expand this breakthrough with the R33 Phase (n=160, 80/group), adding richer maternal outcome measures and MBN fMRI. This research will elucidate the effects of parenting intervention MP on drug use and brain function for OUD mothers - with translational potential for biomarker and treatment development.
Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to levothyroxine sodium. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. A listing of drug-thyroidal axis interactions is contained in Table 2.

The list of drug-thyroidal axis interactions in Table 2 may not be comprehensive due to the introduction of new drugs that interact with the thyroidal axis or the discovery of previously unknown interactions. The prescriber should be aware of this fact and should consult appropriate reference sources (e.g., package inserts of newly approved drugs, medical literature) for additional information if a drug-drug interaction with levothyroxine is suspected.

### Oral anticoagulants

Levothyroxine increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the levothyroxine sodium dose is increased. Prothrombin time should be closely monitored to permit appropriate and timely dosage adjustments (see Table 2).

### Digitalis glycosides

The therapeutic effects of digitalis glycosides may be reduced by levothyroxine. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides (see Table 2).
ABSTRACT OF THE DISCLOSURE         Novel N-amino alkyl indole compounds are disclosed.          Thene compounds correspond to the Formula I                        I     in said Formula R1 indicates the hydrogen atom, an alkyl group with 1 to 4 carbon atoms, which nay be substituted by a phenyl group, or the acetyl group; R2 indicates the hydroxy carbonyl grcup, an alkoxy carbonyl group with 1 to 4 alkyl carbon atoms, the cyano group, the amino carbonyl group, a mono-alkyl amino carbonyl group with 1 to 4 alkyl carbon atoms, or a di-alkyl amino carbonyl group with 1 to 4 alkyl carbon atoms, with the proviso that, when R2 is the hydroxy carbonyl group, then R1 is other than the hydrogen atom; A indicates an alkylene group with 2 to 5 carbon atoms; R3 and R4 are the same or different substi-tuents and indicate the hydrogen atom, an alkyl group with 1 to 4 carbon atoms, or R3 and R4 are an alkylene group forming, to-gether with the nitrogen atom to which they are attached, a heterocyclic ring with 5 to 7 ring members; and R5 and R6 are the same or different substituents and indicate hydrogen and halogen atoms, alkyl groups with 1 to 3 carbon atoms, alkoxy groups with 1 to 3 carbon atoms, of one of said substituents R5 and R6 being the nitro group or the tri-fluoro methyl group while the other one is the hydrogen atom.      The acid addition salts of said compounds are also disclosed. The above mentioned novel N-amino alkyl indole compounds have a favorable effect upon the motility of the gastro-intestinal tract.   the compounds are obtained, for instance, by reacting the alkali metal salts of a corresponding indole compound which is unsub-stituted at its nitrogen atom, with a halogen? alkyl amine.
MS is a frequently disabling autoimmune disease affecting approximately 350,000 people in the United States. More than two decades of research has consistently shown a relationship between stressful life events (SLEs), in particular non-traumatic family and work stressors, and subsequent clinical exacerbation. Furthermore, we have shown that non-traumatic SLEs increase the risk of the subsequent appearance of new gadolinium enhancing (Gd+) magnetic resonance imaging (MRI) brain lesions, an early marker of MS inflammation and blood-brain barrier (BBB) breakdown. The purpose of this study is to determine the efficacy of cognitive behavioral stress management for MS (CBSM-MS) in reducing the occurrence of new brain lesions in people with relapsing forms of MS. Patients must have a documented new Gd+ MRI brain lesion or clinical exacerbation within the previous 12 months to be enrolled. One hundred and twelve patients will be enrolled for 12 months. Patients will be randomly assigned to either an intensive CBSM-MS program, consisting of 16 individual meetings with a behavioral medicine specialist, or a condensed CBSM-MS program, consisting of a one-day workshop offered after the 10th month of participation. Outcomes include MRI, clinical neurological end-points, and psychosocial functioning. We will also enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship between SLEs and clinical and neuroimaging markers of MS inflammation.
After randomization subjects will be divided into control group and intervention group that will receive video tutorial. All subjects will have unlimited access to printed brochures about Advance Directives available at our institution. Use of those materials will be left to their discretion of patients, surrogates and health care professionals involved in patients care. This study was conducted in the medical ICU of tertiary medical center.

Educational video tutorial to cardiovascular resuscitation, defibrillation, endotracheal intubation and mechanical ventilation. Video presents illustrations of resuscitation performed on actors. It informs about the risk, benefits and statistical outcomes of Cardiopulmonary resuscitation (CPR).

Immediately after admission to ICU patients or their health care surrogates were asked to participate in the study. The time between admission and enrollment varied depending on patient's needs and feasibility of conducting research. Upon enrollment subjects were stratified into two groups. One was composed of patients participating in education and testing and another composed of health care surrogates participating on patient's behalf. Those groups were further divided to intervention group that received video education and control group. Stratified randomization occurred according to computer generated list which will be followed for duration of the study. Patients in all four groups had access to printed brochures about Advance Directives. Those pamphlets were available at the admission desk and at the nursing stations. All participants were tested from their knowledge of the code status and related terminology. Subjects randomized to the control group were tested immediately after obtaining consent. Subject from intervention group were tested immediately after video education. Test was administered by the investigator in the format of interview. Completion of the questionnaire took \<10 minutes. Questionnaire contained 17 testing questions. Questionnaire was validated and piloted prior to actual trial.

Satisfaction from education as well as level of discomfort caused by participation in the study were assessed with numeric scales. Following the interview all participants were asked if they would like to discuss Code Status preferences with physician taking care of them. If so, response were noted and appropriate services will be notified immediately. If patients were unable to consent to the study or participate in video education and testing, their health care surrogates were allowed to participate on behalf of the patient. Person giving the consent participated as a subject. Participation of health care proxy were tracked in the collected data. Patient's medical record number was used as personalized code for all the subjects including health care surrogates.
In response to the opioid epidemic, the Centers for Disease Control and Prevention released best practice recommendations for prescribing, yet adoption of these guidelines has been fragmented and frequently met with uncertainty by both patients and providers. This study aims to describe the development and implementation of a comprehensive approach to improving opioid stewardship in a large network of primary care providers. The authors developed a 3-tier approach to opioid management: (1) establishment and implementation of best practices for prescribing opioids, (2) development of a weaning process to decrease opioid doses when the risk outweighs benefits, and (3) support for patients when opioid use disorders were identified. Across 44 primary care practices caring for >223,000 patients, the total number of patients prescribed a chronic opioid decreased from 4848 patients in 2018 to 3106 patients in 2021, a decrease of 36% (P < 0.001). The percent of patients with a controlled substance agreement increased from 13% to 83% (P < 0.001) and the percent of patients completing an annual urine drug screen increased from 17% to 53% (P < 0.001). The number of patients coprescribed benzodiazepines decreased from 1261 patients at baseline to 834 at completion. A total of 6.5% of patients were referred for additional support from a certified alcohol and substance abuse counselor embedded within the program. Overall, the comprehensive opioid management program provided the necessary structure to support opioid prescribing and resulted in improved adherence to best practices, facilitated weaning of opioids when medically appropriate, and enhanced support for patients with opioid use disorders.
The invention relates to a drug-resistant staphylococcus aureus phage SP160 and application thereof in preparing a bacteriostatic agent. The invention separates the phage from a sewage sample, and the phage is used for cracking multi-drug resistant staphylococcus aureusThe titer of the thallus reaches 1.75 multiplied by 10  11  PFU/mL, named SP 160. The phage has a long non-contracting tail, and belongs to the order of caudate phages and the family of long-tail phages. The bacteriophage SP160 has narrow cracking spectrum, the optimal complex infection number is 1000, the cracking kinetic result shows that the bacteriophage SP160 can inhibit the growth of bacteria, has stable activity in the range of-20 ℃ to 54 ℃, has stable activity between the pH value of 3-11, and is sensitive to ultraviolet rays. SP160 has a cleaning effect on the biomembrane of the host bacteria. The phage is a novel long-tail phage with a narrow spectrum and certain tolerance to the environment, and the research on the phage can provide a theoretical material for the research on staphylococcus aureus phage.
PROBLEM TO BE SOLVED: To provide a vegetable hair dyeing agent with which various coloring that henna can not realize is possible or it is possible to modify strongly reddish color of the hair by coloring with henna to darker colors such as brown. SOLUTION: The hair dyeing agent composed of 1 or 2 or more kinds of vegetable hair dyeing agents derived from Isatis tinctoria Linn belongs with Isatis tinctoria Linn. var. yezoensis Ohwi, Polygonum tinctorium Lour with Polygonum tinctorium Lour, Indigofera suffruticosa Mill with Indigofera decora Lindl, Lithospermum officinale Linn. Subsp with Lithospermum arvense Linn, Onosma echioides or Onosma hilspidium with Lithospermum arvense Onosma, Uncaria rhynchophylla Miq or Uncaria gambir belongs with Uncaria rhynchophylla Miq, Rubia argyi Lev Hara with Rubia argyi Lev Haraor, Elaeocarpus sylvestris (Lour.) Poir. var. ellipticus (Thunb. ex Murray) Hara, Strobilanthes cusia (Nees) O. Kuntze with Strobilanthes japonicus (Thunb.) Miq, Pterocarya rhoifolia Sieb. et Zucc, or Camellia sinensis (Linn.) O. Kuntze, or 1 or more of these components is mixed with henna.
Maternal mortality due to cardiovascular disease is a rising concern in the U.S. Pregnancy triggers changes in the circulatory system, potentially influencing the structure of the central vasculature. Evidence suggests a link between a woman's pregnancy history and future cardiovascular health, but our understanding remains limited. To fill this gap, we examined the passive mechanics of the murine ascending thoracic aorta during late gestation. By performing biaxial mechanical testing on the ascending aorta, we were able to characterize the mechanical properties of both control and late-gestation tissues. By examining mechanical, structural, and geometric properties, we confirmed that remodeling of the aortic wall occurred. Morphological and mechanical properties of the tissue indicated an outward expansion of the tissue, as reflected in changes in wall thickness (∼12% increase) and luminal diameter (∼6% increase) at its physiologically loaded state in the pregnant group. With these geometric adaptations and despite increased hemodynamic loads, pregnancy did not induce significant changes in the tensile wall stress at the similar physiological pressure levels of the pregnant and control tissues. The alterations also included reduced intrinsic stiffness in the circumferential direction (∼18%) and reduced structural stiffness (∼26%) in the pregnant group. The observed vascular remodeling maintained the elastic stored energy of the aortic wall under systolic loads, indicating preservation of vascular function. Data from our study of pregnancy-related vascular remodeling will provide valuable insights for future investigations of maternal cardiovascular health.
The present invention relates to medicine for adjusting blood fat and reducing blood plasma fibre protein. The components of the present invention are prepared from 85 to 95% of alisma, 4 to 14% of myrrh and chitosan as the rest. The present invention has the preparation technology that the alisma and the myrrh are dried and are coarsely crushed. Coarse powder are immersed by 90% of ethanol as washing liquid for one night. The coarse powder is leached in a dynamic state, and residues are removed. The ethanol is filtrated and recovered by an extracting solution, and then the ethanol is concentrated into a thick paste shape. After chitosan is added in the thick paste and is evenly mixed, obtained thick paste is dried below 70 DEG C. The obtained thick paste is crushed into fine powder of 100 meshes and is encapsulated to obtain a finished product. The new medicine has the advantages of outstanding curative effect and no side effect and can be used as medicine for lowering blood fat and blood plasma fibre protein.
Patients who have received a kidney transplant or a re-transplant less than 5 years before inclusion in the study and have shown a stable clinical course after 6 months from the RT, defined as: patients without previous rejection episodes nor indication biopsies, who do not show signs of renal impairment and are dnDSA negative, without changes in immunosuppressive drugs in the last 6 weeks and without opportunistic infections in the last six months before entering in the study. An IMBG will be performed coinciding with the only visit.
The invention relates to an O/Asia I type foot and mouth disease virus bivalent genetic engineering polypeptide vaccine, its preparation method and its purpose. The method comprises the following steps: selecting two serotypes of O type and Asia I type, taking B cell determinant 15 amino acid fragments of VP1 and T-cell helper of VP4, performing a series connection, cloning without containing carrier protein, constructing O/Asia I gene engineering bacteria. An antigen protein product can be obtained after passing through the processes of high density fermenting, cell disrupting, inclusion body renaturating, fusion protein separating, and is homogenized with an adjuvant to form the O/Asia I type foot and mouth disease virus bivalent genetic engineering polypeptide vaccine. The vaccine of the present invention contains 2<n-1> polypeptide connected in series which is coded by a nucleic acid sequence shown in SEQ ID, wherein, n is an integer of 1-5. The invention has the advantages of good security and high immune efficacy, and can be used once in half year for immunization; and is suitable for large scale production and convenient preservation and transportation; and is capable of effectively preventing and controlling two serotypes foot and mouth disease of O type and Asia I type which is useful in our country; foot and mouth disease virus non-structural protein 3A.B. will not generate, so that the infective animals can be differentiated easily.
Drug abuse remains a major society problem in our community and is also a major health problem in our modern society. Thus, education to prevent the young generation to avoid drug abuse and detoxification to help those to quite from the drug abuse are two major key steps in the controlling drug abuse program.

Currently, medications for opiate detoxification, such as methadone, are commonly used worldwide. However, methadone is also an addictive medication. When it is stopped suddenly, patients usually produce unpleasant withdrawal symptoms. Meanwhile, methadone is also potentially to be abused too. Thus, it is urgently needed to seek an alternative safer, effective, drug-free method for opiate detoxification. Based on our clinical observation, the timely clearance of toxicities from the body or blood is a safe and effective detoxification method. Thus, we hypothesized that the use of combined hemoperfusion-hemodialysis may be an alternative drug-free, effective, and safe treatment for opiate detoxification. This will be tested in patients who have severe drug abuse and are under custodial conditions by a daily combined hemoperfusion-hemodialysis for 3 days. The efficacy and safety of the hemoperfusion-hemodialysis will be compared to a 10 day standard methadone detoxification treatment.
PURPOSE:To obtain a dispersion of solid in liquid in which an oil-soluble substance is homogeneously and stably dispersed in an aqueous solution in a solid state. CONSTITUTION:In this dispersion of solid in liquid, an oil-soluble substance is dispersed in an aqueous solution of a watersoluble hemicellulose in a solid state. The oil-soluble substance is a substance which has a solid content of >=90wt.% at 20 deg.C and a melting point of >=40 deg.C, especially, >=100 deg.C and is insoluble or slightly soluble in water. The oil-soluble substance is e.g. a chemical which is effective as an agrochemical or an insecticide (e.g. 1-naphthyl-N-methyl carbamate or tetrachloroisophthalonitrile) or a high-melting oil and fat which is effective as an indigestible oil and fat. A bean e.g. soybean, especially, originated from a cotyledon is preferable as the above mentioned water-soluble hemicellulose. Preferably 0.05-25 pts.wt., especially, 1-20 pts.wt. of the oil-soluble substance is dispersed against 1 pts.wt. of the water-soluble hemicellulose. The oil-soluble substance is preferably pulverized into fine particles having an average particle diameter of <=40mum, especially, <=10mum. By dehydrating the dispersion of solid in liquid, a hydrate capable of easily being wetted and dispersed into water is obtained.